6533b855fe1ef96bd12b147b

RESEARCH PRODUCT

Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI.

Vincenzo RestivoPalmira ImmordinoGiorgio GrazianoVitale FrancescoEmanuele AmodioCarmelo Massimo MaidaWalter MazzuccoDaniela Di NaroClaudio CostantinoFabio TramutoGiulia RandazzoCasuccio Alessandra

subject

medicine.medical_specialtyrespiratory syncytial virusImmunologySettore MED/42 - Igiene Generale E ApplicataVirusArticleInternal medicineDrug DiscoveryEpidemiologymedicinerisk factorsPharmacology (medical)In patientRespiratory systemPharmacologyMolecular epidemiologybusiness.industryPublic healthRvirus diseasesmolecular surveillancevaccinationrespiratory tract diseasesVaccinationInfectious Diseasesrisk factorEtiologyMedicinecommunityrespiratory syncytial virubusinesshospitalization

description

Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups &lt

yearjournalcountryeditionlanguage
2021-11-16Vaccines
10.3390/vaccines9111334https://pubmed.ncbi.nlm.nih.gov/34835265